## Vasculitides

Anna Chacon, MD

nna Chacon, MD							
Diagnosis	Epidemiology	Pathogenesis	Clinical Features	Diagnostic Approach	Pathology	Therapy	Complications/ Associations
SMALL VESSEL VA							
Henoch-	Issel vasculitis ((CSW), Most common in children < 10 yrs; associated w/ preceding respiratory infection - 75% by GAS. May be seen in adults. Slight male predominance.	cutaneous leukocytoclas IgA-dominant immune depositis in small blood vessel walls. Dx supported by IgA predominance in the correct clinical setting.	1 - Intermittent	ittis, hypersensitivity angr Palpable purpura (required) w/ at least 1 of the following: arthritis/ arthralgia, diffuse abdominal pain, renal involvement, bx w/lgA deposition.	itits, allergic vasculitis Necrotizing vasculitis. Immunoreactants deposited in skin are IgA. DIF: perivascular IgA, C3 & fibrin deposits.	<ul> <li>cutaneous necrotizing venu</li> <li>Self-limited, supportive.</li> <li>Dapsone &amp; colchicine</li> <li>may decrease duration</li> <li>of skin lesions. Systemic</li> <li>steroids: Rx for arthritis</li> <li>&amp; abdominal pain.</li> <li>Nephrology referral w/</li> <li>renal involvement.</li> </ul>	Initis) Renal vasculitis often mild but can be chronic. May be associated w/under/ying malignancy in adults.
Acute hemorrhagic edema of infancy (Finkelstein's dz, Seidlmayer syndrome, purpura en cocarde avec edema, postinfectious cockade purpura)	Seen primarily in children 4-24 months of age. Child is well appearing.	Unknown. 75%: associated w/infxn, drug exposure, or immunization. Thought to involve immune complex deposition responding to antigenic trigger.	Benign clinical course. Annular,	Routine labs: nonspecific. Dx based on clinicopathologic correlation. Characteristic: age onset < 2 yrs., disease confined to skin, brief duration.	LCV involving capillaries & postcapillary venules of upper & mid-dermis. DIF: IgA deposits in vascular pattern in 1/3 – 1/4 of cases.	Spontaneous resolution within 1-3 weeks. Antihistamines for symptomatic relief.	Extracutaneous involvement rare. Two-thirds of pts have infectious prodrome.
urticaria as a manifestation of	Uncommon. Peak incidence: 5 <sup>th</sup> decade. 60-80% female. Hypocomplementemic form: almost exclusively in women.	Complement activation triggers mast cell release of inflammatory mediators. Idiopathic or associated with SLE, Silgren's, cryoglobulinemia, or Wegener's granulomatosis.	Painful/burning urticarial lesions lasting >24 hrs; resolve leaving behind hemosiderin, causing red- brown maculae/ postinflammatory hyperpigmentation.	Lab: ESR, CRP, SPEP, ANA, autoantibodies (anti-SS-A/Ro, anti-SS-B/La), complement levels (CH50, C3, C4), Further evaluation can include: CXR, PFTs, RFTs.	Typically hive w/edema but also w/LCV. A perivascular lymphocytic infiltrate is not enough for dx.	Difficult. Try: antihistamines, dapsone, NSAIDS, antimalarials. Unresponsive/ systemic: steroids & perhaps additional immunosuppressants.	Many pts have hives persisting >24 hrs, but few have urticarial vasculitis w/signs & sxs. Systemici: abdominal distress. Lung involvement can be fatal.
Erythema elevatum diutinum (extracellular cholesterosis)	Uncommon, rare. Can develop at any age. No racial/gender predilection.	Suspicion that streptococci are trigger for chronic immune complex reaction. Occurs in HIV/AIDS, unclear if result of other factors vs. immunosuppression.	Symmetrical, slowly developing red- brown papules & nodules favoring backs of hands, over digital joints, knees, & elbows. Rarely more widespread. Usually asymptomatic.	Skin biopsy. Serum protein electrophoresis (SPEP).	LCV w/thickening of vessel walls; later – fibrosis, granulomatous inflammation, occasional cholesterol deposits.	Limited: intralesional or high-potency topical steroids. Widespread/ resistant: dapsone. Nicotinamide & tetracycline may help.	Association with IgA monoclonal gammopathy or even multiple myeloma. Earlier onset more often in HIV setting.
	of CSSV: Drugs; infectio -SIZED VESSEL VASCU	ns; malignancies, most o	often hematologic				
Cryoglobulinemia [types I, II, III; types II & III:	Frequency varies w/geography, may reflect prevalence differences in HCV. Higher prevalence in Southern Europe.	Circulating Ig complexes that precipitate when incubated at <4° C. Compositions: I – monoclonal IgG or IgM; II – monoclonal IgM + polyclonal IgG; III – polyclonal IgG;	Type I: thrombosis, livedo, Raynaud syndrome, ulcers. Types II-III: chronic immune complex vasculitis, skin & kidneys.	Blood must be transported to lab at 37°C then cooled to < 4°C; cryocrit is then determined & protein selectively analyzed. Reactive hypocomplementemia.	Papular lesions show LCV, while necrotic or ulcerated lesions may demonstrate medium-sized vessel vasculitis. DIF: granular deposits w/lgM & C3 in vascular pattern in papillary dermis.	Avoid cold. Treat underlying disease. If HCV involvement: interferon + ribavirin. Progressive: MTX or cyclophosphamide + systemic steroids, +/- plasma exchange.	Peripheral neuropathy & glomerulonephritis can develop. Types II-III: most commonly in the setting of HCV infection, 80%.
Microscopic polyangiitis (microscopic polyarteritis, microscopic polyarteritis nodosa)	Estimated incidence 3-24/million. Men > women. Mean age of onset = 57 years, peak 65-75 yrs.	Unknown. May be associated w/infectious endocarditis. Medications/ malignancy may be a trigger. ANCA is thought to play a role.	Palpable purpura, erythematous macules & patches, splinter hemorrhages & ulcers. Constitutional sxs, crescentic necrotizing glomerulonephritis & alveolar hemorrhage.	Presence of P.ANCA. Additional testing: CXR, EMG/nerve conduction studies, lung/nerve/kidney bx.	Segmental necrotizing vasculitis of smallest blood vessels & less often of small/ medium-sized arteries. Absence of granuloma formation.	2 phases: 1) Remission – initially steroids, cyclophosphamide or rituximab for significant organ involvement. 2) Maintenance: MTK, azathioprine, MMF, IVIg. Plasma exchange may be beneficial.	More severe renal vasculitis favors older pts. ANCA persistence despite remission – increased risk of relapse.
Wegener's granulomatosis (granulomatosis with polyangiitis)	Incidence = 0.3/100,000 annually; USA: prevalence 1/25,000. Most often in Caucasians. Slight female predominance.	Unknown. Infections, including S. aureus, are suspected triggers.	Stages - 1 <sup>st</sup> : general signs & sxs - fever, malaise, upper airway problems. 2 <sup>nd</sup> : lower airway: cough, dyspnea, hemoptysis, pleurisy. 3 <sup>rd</sup> stage: generalized involvement incl. skin. Skin: polymorphic picture including LCV, urticarial vasculitis, necrotizing pyodermas, panniculitis. Oral ulcers, recurrent epistaxis, nasal septal perforation	Tissue dx: usually airway/renal bx, sometimes skin helps. Investigate: upper airways, kidneys, lungs. C-ANCA positive in 50% during early phase, >90% when generalized.	Triad: necrotizing LCV, necrosis, granuloma formation. Granulomas can be in vessel walls or adjacent; palisading, or rich in giant cells. Irregular necrosis – "geographic."	Fauci regimen: prednisone & cyclophosphamide. Unresponsive: agents can be increased. If + response, taper steroid. Other immunosuppressants under investigation: Cyclophosphamide induction followed by MTX. Recurrence/ localized: co-trimoxazole.	Frequency of organ involvement lungs 95%, upper airway 90%, kidneys 85%, joint 70%, eyes 60%, ears 60%, skin 45%, nerves 20%, heart 10%.



Anna Chacon, MD, is a preliminary resident at Orlando Regional Medical Center. She will be a dermatology resident at the University of Maryland Medical Center beginning July 2014.



## boards' fodder

## Vasculitides (cont.)

Anna Chacon, MD

Diagnosis	Epidemiology	Pathogenesis	Clinical Features	Diagnostic Approach	Pathology	Therapy	Complications Associations
SMALL & MEDIUN	I-SIZED VESSEL VASCU	LITIS ("MIXED")					
Churg-Strauss syndrome (allergic granulomatosis & angiitis, granulomatous vasculitis of Churg-Strauss)	Extremely rare. 0.3/100,000 yearly, perhaps associated w/atopy.	Unknown. Speculation: role of leukotriene antagonists, vaccines, rapid D/C of corticosteroids, desensitization may trigger disorder.	Asthma > 80%, often presenting symptom. Later: pulmonary infiltrates, vasculitis. Transient pulmonary eosinophilic infiltrates occur. Granulomatous inflamxn of myocardium = leading cause of death Skin: involved in 70% - purpura, nodules, urticarial vasculitis.	Tissue dx: skin or lung. Investigate lungs & other organs based on signs & sxs. Labs: elevated ESR, hypereosinophilia, elevated IgE, cryglobulins, immune complexes. Both cANCA & pANCA can be positive, about 20% for each.	distance. Marked eosinophilia, nuclear dust,	Very steroid responsive – i.e. prednisolone. Reserve immunosuppressants for tx failures or life- threatening dz. Both IFN-a & IVIg have shown promise.	Multi-organ involvement: mononeuritis multiplex 60%, kidneys 50%, heart 40%, GI tract 40%. Localized granulomas: sometimes limited to skin, mostly associated w/RP also infections, jymphoma, idiopathic.
	: Infections, Inflammatory VESSEL VASCULITIS	disease (e.g., Al-CTD)					
Polyarteritis nodosa [(PAN), panarteritis nodosa, Kussmaul-Maier dz)	Rare. Incidence = 0.5/100,000 yearly. Mostly affects middle-aged men. Associations: HBV, HIV/AIDS; strep	Involvement in segments. Favors areas where branching occurs. Small aneurysms frequently develop.	Fevers, wt loss, arthralgias. Skin: frequent involvement; livedo racemosa, digital gangrene, SQ nodules, ulcers, LCV. Cutaneous PAN: limited to skin; benign, chronic course; nodules & punched-out ulcers usually on legs.	Histologic confirmation: usually skin or muscle bx. Imaging: angiography can reveal microaneurysms in GI or renal aa. Labs: few changes, high ESR, anemia, thrombocytosis, microscopic hematuria. Check HBsAg. ANCA+ <5%.	Segmental involvement makes it hard to find lesions. Initial inflammatory infiltrate is neutrophilic, later replaced by mononuclear cells w/intimal proliferation, finally granulomas & fibrosis.	Systemic steroids; can start w/pulse therapy. Unresponsive or major organ involvement: add cyclophosphamide or other immunosuppressants. If HBsAg+: start w/ prednisone & plasma exchanges, followed by IFN & lamivudine – hepatology consult.	Thrombosis leads to infarcts & vessel-wall obliteration. GI tract: "intestinal angina," ischemic bowel perforation, mesenteric a. thrombosis or rupture. Peripheral neuropathy. Kidney: 10%. Heart: MI or CHF CNS: stroke risk, HTN changes.

Sterry W, Paus R, Burgdorf W: Purpura and Vasculitis. In: Dermatology. edn. New York, NY:: Thieme.; 2006: 245-261.
 Wolff K, RA Johnson.: The Skin Signs in Immune, Autoimmune, and Rheumatic Disorders. In: Color Atlas & Synopsis of Clinical Dermatology. edn. United States of America: McGraw Hill; 2009: 397-410.
 Shinkai K, Fox L: Cutaneous Vasculitis. In: Dermatology. Volume 1., edn. Edited by Bolognia JL, Jorizzo JL, Schaffer JV: Elsevier.; 2012: 385-409.

## **Double dose** of Boards' Fodder!

In addition to this issue's Boards' Fodder, Vasculitides, don't forget to download the new Board's Fodder online exclusive from www.aad.org/ DIR, where a new chart is published each quarter. The Summer 2014 online Boards' Fodder is phototherapy by Rebecca Bialas, MD.

To view, download, or print every Boards' Fodder ever published, both in print and online, check out the complete archives at www.aad.org/ **BFarchives**.

